Carvedilol treatment was introduced from 1.25 mg or 2.5 mg daily, and the dose was gradually increased to 5 mg, 10 mg, the target dose of 20 mg if systolic blood pressure stayed at >90 mmHg, and if heart rate >60 beats/min, serum creatinine level <3.0 mg/dl, and HF-related symptoms were stable. Simi- The aim of the present study was to verify the effects of β-blockers on renal function in patients with heart failure (HF).
t is well recognized that heart failure (HF) with chronic kidney disease is associated with poor clinical outcomes, which is referred to as "cardio-renal continuum". 1,2 Because β-blockers are established as an essential therapeutic option for patients with HF, 3-5 it is critical to characterize the effects of such compounds on renal function in patients with HF. The effects of β-blockers on renal function, however, are variable due to the inherent pharmacologic profiles. 6- 10 To date, few studies have focused on the effects of β-blockers on renal function in patients with HF. The aim of the present study was therefore to verify the effect of β-blockers on renal function in patients with HF.
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Patient Characteristics
Patients with HF who received regular medical treatment without β-blockers at Keio University Hospital in 2003, in whom New York Heart Association (NYHA) functional class ranged from II to III and left ventricular ejection fraction (LVEF) was <40%, were enrolled in the present study. Eightynine patients were enrolled, and randomized to receive carvedilol tartrate or short-acting metoprolol tartrate. Because the present study was a retrospective analysis, data on renal function during the follow-up period were missing in many patients. A complete set of data was collected from 40 patients (age, 64±11 years old; gender, M/F n=35/5; NYHA class II/III, n=31/9; LVEF, 28±8%; etiology, ischemic cardiomyopathy/dilated cardiomyopathy 11/29; carvedilol group, n=23; metoprolol group, n=17). There was no difference in baseline characteristics between included and excluded patients (Supplemental Table S1 ).
Beta-Blockers on Renal Function in CHF
larly, metoprolol treatment was introduced from 5 mg daily, and the dose was gradually increased to the target dose of 80 mg. These are accepted target doses in Japanese patients with HF. 11,12 Both β-blockers were given twice daily after each target dose had been achieved. The mean final dose of carvedilol was 19±3 mg and that of metoprolol was 70±23 mg. More than 80% of the patients reached the target doses in each group, therefore, both β-blockers were considered to be well tolerated whether the patients had renal dysfunction or not.
The study population was divided into 2 groups, namely the lower estimated glomerular filtration rate (eGFR) and higher eGFR groups according to the median baseline eGFR (65.9 ml·min -1 ·1.73 m -2 ) calculated using the Modification of Diet in Renal Disease formula: eGFR (ml·min -1 ·1.73 m -2 )= 186.3×(serum creatinine) -1.154 ×(age) -0.203 ×0.742 (if subject is female) or ×0.881 (if subject is Japanese). 13 The baseline characteristics are listed in Table 1 . Cardiac function, biomarkers including plasma brain natriuretic peptide (BNP; chemiluminescence enzyme immunoassay), highsensitivity C-reactive protein (nephelometry), interleukin-6 (chemiluminescence enzyme immunoassay), and lipid peroxide (hemoglobin-methylene blue) and plasma norepinephrine (high performance liquid chromatography) were examined before and 16 weeks after introduction of β-blockers to see if β-blocker therapy affected neurohormones, cytokines, and oxidative stress. The left ventricular end-diastolic (LVEDD) and end-systolic diameters (LVESD) were measured on echocardiography. The left ventricular end-diastolic (LVEDV) and end-systolic volumes (LVESV) were calculated using the Teichholz formula V=7.0×D 3 /(2.4+D), where V represents volume and D represents diameter, 14 and then stroke volume (SV[ml]=LVEDV-LVESV) and cardiac output (CO) were calculated (CO[L/min]=SV×[heart rate]). LVEF was measured on radionuclide ventriculography. We excluded patients with secondary cardiomyopathy due to various etiologies such as cardiac sarcoidosis, alcoholism, and skeletal myopathy, acute coronary syndrome, acute exacerbation of HF within the previous 3 months, suspected malignancy, and hepatic impairment from the study population. Dilated cardiomyopathy and ischemic cardiomyopathy were diagnosed using coronary angiography and endomyocardial biopsy according to the definition proposed by the World Health Organization/ International Society and Federation of Cardiology. 15 
Ethics
The study protocol conformed to the ethics guidelines of the 1975 Declaration of Helsinki, and the protocol was a priori approved by the institutional review committee. Informed consent was obtained from all patients who participated in the present study.
Statistical Analysis
All data are expressed as mean ± SD. Statistical comparisons were performed within groups using Student's paired t-test, and among groups using repeated measure ANOVA or Student's unpaired t-test. Chi-square test was used for comparison of dichotomous variables between 2 groups in Table 1 . Statistical significance was defined as P<0.05. ITO H et al.
Results
Lower eGFR vs Higher eGFR
There were no differences in age, gender, etiology, or severity of HF between the lower eGFR and the higher eGFR groups ( Table 1) . LVEF measured on radionuclide ventriculography was also similar between the 2 groups. Plasma BNP level tended to be higher in the lower eGFR group than the higher eGFR group, although statistically it was not significant. Serum creatinine concentration was higher in the lower eGFR group than the higher eGFR group. Cardiovascular medications were similarly prescribed including carvedilol and metoprolol.
LVEDD did not change in the lower eGFR group (from 6.1±0.8 cm to 6.0±0.8 cm), but significantly decreased in the higher eGFR group (from 6.3±0.7 cm to 5.9±0.6 cm, P<0.01). Although LVESD tended to decrease in the lower eGFR group (from 4.9±1.0 cm to 4.8±1.0 cm, P=0.09), they significantly decreased in the higher eGFR group (from 5.2±0.8 cm to 4.6±0.7 cm, P<0.01). LVEDV did not change in the lower eGFR (from 188±56 ml to 183±52 ml), but significantly decreased in the higher eGFR groups (from 205±59 ml to 177±39 ml, P<0.01). LVESV tended to decrease in the lower eGFR group (from 118±55 ml to 98±35 ml, P=0.09), but significantly decreased in the higher eGFR group (from 131± 61 ml to 111±39 ml, P<0.01). SV did not change in the lower Figure 2 . Plasma norepinephrine concentrations during β-blocker therapy according to the baseline estimated glomerular filtration rate (eGFR) levels. There was an interaction between plasma norepinephrine concentration and eGFR in terms of β-blocker treatment (P=0.02, ANOVA). wk, weeks.
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eGFR group (from 70±18 ml to 71±22 ml), but it tended to increase in the higher eGFR group (from 70±15 ml to 79± 19 ml, P=0.09). CO did not change in either the lower eGFR group (from 5.8±2.0 L/min to 5.0±2.2 L/min) or higher eGFR group (from 5.7±1.6 L/min to 5.5±1.5 L/min). LVEF was significantly increased 16 weeks after introduction of β-blockers in both the lower eGFR group (from 28±7% to 36±8%, P= 0.01) and higher eGFR group (from 28±8% to 36±8%, P<0.01; Figure 1 ). There was no difference in the change of LVEF between the 2 groups (6.6±9.6% vs 7.7±10.5%). No interaction was observed between groups in terms of LVEF, LVEDD, LVESD, LVEDV, LVESV, SV, or CO using ANOVA.
eGFR did not change in the lower eGFR group after introduction of β-blockers from baseline (from 49.0±12. Baseline plasma norepinephrine level was higher in patients with lower baseline eGFR than those with higher baseline eGFR (747±330 pg/ml vs 478±179 pg/ml, P<0.01). Plasma norepinephrine level was decreased in the patients with lower baseline eGFR, but not in those with higher baseline eGFR (Figure 2) . There was a significant interaction of plasma norepinephrine levels in terms of baseline eGFR and treatment with β-blockers using repeated-measure ANOVA (P=0.02). Plasma BNP level did not change in either the lower eGFR group (from 213±341 pg/ml to 179±145 pg/ml) or the higher eGFR group (from 140±235 pg/ml to 112±123 pg/ml). Other cardiovascular markers including high-sensitivity Creactive protein, interleukin-6, or lipid peroxide level, also did not change.
Carvedilol vs Metoprolol
Next, we examined the influence of 2 different kinds of β-blocker on renal function. Baseline eGFR did not differ significantly between patients who received metoprolol and those who received carvedilol (P=0.38). eGFR significantly decreased from 75.7±33.5 ml·min -1 ·1.73 m -2 to 59.5±20.0 ml· min -1 ·1.73 m -2 (P<0.01) in patients who received metoprolol, but did not change in those who received carvedilol (from 67.1±27.7 ml·min -1 ·1.73 m -2 to 65.6±23.2 ml·min -1 ·1.73 m -2 ; Figure 3A) . Analysis of variance, however, did not indicate any significant interactions by the 2 different kinds of β-blocker in terms of the changes in eGFR over the 16 weeks after introduction of β-blockers. ∆eGFR was significantly greater in the patients who received metoprolol than those who received carvedilol (-16.2±19.0 ml·min -1 ·1.73 m -2 vs -1.4±22.2 ml·min -1 ·1.73 m -2 , P=0.03; Figure 3B) . ∆eGFR was also different when we normalized by each baseline value (-0.16±0.22 vs 0.09±0.57, P=0.02). LVEF was similarly increased in both patients who received metoprolol (from 29.0±7.5% to 36.8±6.5%, P<0.01) and carvedilol (from 27.4± 7.8% to 34.1±10.3%, P=0.01) over the 16 weeks after introduction of β-blockers. Plasma BNP level did not change in patients who received metoprolol (from 165±259 pg/ml to 180±178 pg/ml), and in those who received carvedilol (from 137±232 pg/ml to 114±90 pg/ml). There were no differences in the change of LVEF, plasma norepinephrine, BNP, high- 
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sensitivity C-reactive protein, or lipid peroxide levels between the patients who received metoprolol and those who received carvedilol according to the baseline eGFR levels. Univariate analysis was performed for the 18 variables with a dependent factor of change in eGFR listed in Table 2 , which showed that selection of β-blocker (P=0.09), baseline eGFR (P<0.001), age (P=0.03), baseline systolic blood pressure (P=0.01), baseline LVEF (P=0.01), use of diuretics (P= 0.07), use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (P=0.09) and spironolactone (P=0.06) were related to change in eGFR, and were candidates for multivariate regression analysis. It was shown that selection of β-blocker was a predictor of change in eGFR, independently from baseline eGFR.
Discussion
Difference in Efficacy According to Baseline Renal Function
Presence of chronic kidney disease adversely affects clinical outcomes in patients with HF. 2 One of the major reasons why such patients are associated with poor clinical outcomes is underuse of β-blockers, as well as a higher burden of comorbidities, increased toxicities from diagnostic procedures or therapies, accelerated atherosclerosis, and activations of various neurohormones, cytokines, and oxidative stress. Efficacy of various pharmacotherapies on survival was examined in 6,427 patients with HF due to coronary artery disease. Use of β-blockers was associated with better survival than nonusers even in patients with eGFR <60 ml·min -1 ·1.73 m -2 . 16 In patients who receive chronic hemodialysis, the β-blocker carvedilol significantly improved survival free from cardiovascular hospitalizations as compared with placebo. 17 The present study has confirmed that β-blockers improve cardiac function similarly in patients with lower baseline eGFR and those with higher baseline eGFR. Plasma BNP concentration did not change significantly during the short-term administration of β-blockers, as we previously reported. 18, 19 It is of note that baseline plasma norepinephrine concentration was higher in patients with lower baseline eGFR than those with higher baseline eGFR, and plasma norepinephrine level was decreased 16 weeks after introduction of β-blockers in patients with lower baseline eGFR but not in those with higher baseline eGFR. Although the sample size is limited in the present study, such differences in sympathoadrenal activations may have some impact on the efficacy of β-blocker when we test the hypothesis using larger sample size.
Differential Effects of β-Blockers on Renal Function
Although the beneficial effect of β-blockers on cardiac function has been established in patients with chronic HF, there have been few studies that have examined the effect of β-blockers on renal function. Clinical studies using small sample sizes have shown that vasodilating carvedilol does not decrease renal blood flow (RBF) or glomerular filtration rate (GFR), and actually decreases renal vascular resistance in patients with essential hypertension. 9, 10 In contrast, β1-selective agent, metoprolol and atenolol increased renal vascular resistance without affecting RBF or GFR. 6,7 There have been few published studies, however, that directly compared carvedilol with metoprolol. Carvedilol decreased renal vascular resistance in comparison with metoprolol in a randomized crossover study involving 12 patients who received allograft renal transplantation. 20 Unpublished observation that involved only 14 patients with HF reported that only carvedilol increased RBF and GFR, with similar effects on cardiac function by metoprolol. The present study involving 40 patients with HF has clearly shown that carvedilol affects renal function more favorably as compared with metoprolol.
Recently, subanalysis of the metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF) has shown that renal function was a powerful predictor of death and hospitalization from worsening HF, and that metoprolol CR/XL was at least as effective in reducing death and hospitalization for worsening HF in patients with lower eGFR as in those with higher eGFR. 21 That mega study had a great impact, but one of the limitations of that study is that serum creatinine was measured at baseline only, and was not measured during follow up. In comparison with that study, the present study measured serum creatinine before and 16 weeks after introduction of β-blockers, and could estimate the effect of β-blockers on renal function. Furthermore, we did not compare β-blocker with placebo but compared 2 different kinds of β-blocker, and found that carvedilol exerted more renoprotective effect than metoprolol.
Mechanisms Underlying Renoprotective Effect of Carvedilol
Carvedilol but not metoprolol appeared to maintain RBF by vasodilating renal arterioles. Such differential effects on RBF may account for the difference in renoprotective effects between carvedilol and metoprolol. Previous studies have shown that carvedilol prevents microalbuminuria in patients with hypertension, diabetes and/or chronic kidney disease. A large-scale, randomized clinical trial compared carvedilol and metoprolol tartrate added to a treatment regimen containing a renin -angiotensin system antagonist in 12,335 diabetic patients with established hypertension. The mean urinary albumin/creatinine ratio decreased by 1% in patients who received carvedilol, whereas the ratio increased by 2.5% in those who received metoprolol. 22 Oxidative stress plays a major role in mediating microalbuminuria in patients with essential hypertension. 23 Carvedilol, which has an antioxidant effect, may be more useful than metoprolol in preventing microalbuminuria. 24 In addition, a previous study showed that Abbreviations see in Table 1 .
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carvedilol prevents renal fibrosis through inhibiting transdermal growth factor-β expression in hypertensive-stroke prone rats. 25 In the present study carvedilol did not decrease eGFR in the patients with HF, whereas metoprolol significantly decreased eGFR. Therefore, we can conclude from the present results that carvedilol has more renoprotective effect than metoprolol in the treatment of HF, although we could not find any differences between metoprolol and carvedilol in terms of plasma norepinephrine, BNP, or lipid peroxide concentrations.
Conclusions
β-Blockers preserved renal function in HF patients with underlying renal dysfunction, but not in those with intact renal function. Carvedilol may be preferable to metoprolol to prevent chronic kidney disease in patients with HF.
